Cargando…

Deletions of 9p21 and TP53 in bladder cancer.

The objective of this study was to characterize the alterations of 9p21 and TP53 in Korean transitional bladder cancer and to assess the relationship between the histopathologic parameter and the alteration of these genes. Allele loss in 29 surgically resected transitional cell carcinoma was examine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, W. S., Oh, M. J., Lee, H. K., Lee, K. O., Rhyu, M. G., Dong, S. M., Lee, J. Y., Kim, S. H.
Formato:	Texto
Lenguaje:	English
Publicado:	Korean Academy of Medical Sciences 1996
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3054043/ https://www.ncbi.nlm.nih.gov/pubmed/8843005

Ejemplares similares

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

P814: ANALYSIS OF TP53 ALTERATIONS BY WGS REVEALS BIALLELIC 17P DELETIONS IN MULTIPLE MYELOMA
por: Truger, Marietta, et al.
Publicado: (2023)

Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion
por: Hao, Suyang, et al.
Publicado: (2017)

Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer
por: Hwang, Hye Jung, et al.
Publicado: (2020)

p53 in head and neck cancer: Functional consequences and environmental implications of TP53 mutations
por: Peltonen, Jenni K, et al.
Publicado: (2010)

Non-Nodal CD5-Negative Mantle Cell Lymphoma with Secondary TP53 Deletion
por: McCall, Robert K., et al.
Publicado: (2020)

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
por: Köbel, Martin, et al.
Publicado: (2016)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

Mutation analysis of P73 and TP53 in Merkel cell carcinoma
por: Gele, M Van, et al.
Publicado: (2000)

Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis
por: Yang, Y C, et al.
Publicado: (2006)

From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion
por: Quinn, Emily A., et al.
Publicado: (2019)

Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer
por: Kim, Kyoung Min, et al.
Publicado: (2022)

Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
por: Abdel-Fattah, R., et al.
Publicado: (1998)

p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma
por: Boldrin, Elisa, et al.
Publicado: (2023)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer
por: Xia, Li C., et al.
Publicado: (2020)

Elephant TP53-RETROGENE 9 induces transcription-independent apoptosis at the mitochondria
por: Preston, Aidan J., et al.
Publicado: (2023)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2
por: Schuyer, M, et al.
Publicado: (2001)

Genetic Variation in the TP53 Pathway and Bladder Cancer Risk. A Comprehensive Analysis
por: Pineda, Silvia, et al.
Publicado: (2014)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Development of chronic myelogenous leukemia in a case of chronic lymphocytic leukemia with Tp53 gene deletion
por: Gupta, A, et al.
Publicado: (2015)

Germline TP53 mutations in Finnish breast cancer patients
por: Rapakko, K, et al.
Publicado: (2000)

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
por: Wang, Jeffrey, et al.
Publicado: (2019)

An immunohistochemical study of the expression of p53 protein in colon cancer.
por: Kim, Y. W., et al.
Publicado: (1995)

A Mouse Homolog of a Human TP53 Germline Mutation Reveals a Lipolytic Activity of p53
por: Kang, Ju-Gyeong, et al.
Publicado: (2020)

Significance of TP53 mutation in bladder cancer disease progression and drug selection
por: Wu, Guang, et al.
Publicado: (2019)

TP53 drives invasion through expression of its Δ133p53β variant
por: Gadea, Gilles, et al.
Publicado: (2016)

A Novel ATM/TP53/p21-Mediated Checkpoint Only Activated by Chronic γ-Irradiation
por: Cao, Lili, et al.
Publicado: (2014)

TP53 loss creates therapeutic vulnerability in colorectal cancer
por: Liu, Yunhua, et al.
Publicado: (2015)

p53 mutations in urinary bladder cancer
por: Berggren, P, et al.
Publicado: (2001)

P1024: IMPACT OF TP53 IN MYELOFIBROSIS UNDERGOING STEM CELL TRANSPLANTATION
por: Gagelmann, N., et al.
Publicado: (2022)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: Effects in human colorectal HCT116 TP53(+/+), TP53(+/−) and TP53(−/−) cells
por: Willis, Alexandra J., et al.
Publicado: (2018)

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
por: Chin, M, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a1vd2h4eskbel2d26pq1n6vad3